Trial Profile
Double Blind, Placebo-controlled, Dose Finding, Prospective, Multicenter Clinical Trial for the Treatment of Rhinitis/Rhinoconjunctivitis Against a Mixture of Dermatophagoides Pteronyssinus and Dermatophagoides Farinae Allergen Extract
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Sep 2022
Price :
$35
*
At a glance
- Drugs MM 09 (Primary) ; MM 09 (Primary)
- Indications Hypersensitivity; Rhinitis; Rhinoconjunctivitis
- Focus First in man; Therapeutic Use
- Sponsors Inmunotek
- 01 May 2022 According to an Inmunotek media release, Dr. Antonio Nieto is the principal investigator for this trial.
- 16 Mar 2020 Primary endpoint (Concentration required to elicit a positive response after nasal provocation test (NPT)) has been met.
- 16 Mar 2020 Results presented at the 2020 Annual Meeting of the American Academy of Allergy, Asthma and Immunology